Results for this period
Full year1 March 2025–28 February 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased due to the full-year contribution from acquired companies and new acquisitions through M&A, as well as higher prescription prices at dispensing pharmacies. The healthcare business reported lower profit due to higher personnel expenses, M&A expenses and upfront costs for newly established facilities, while the pharmaceutical wholesale business was affected by lower official drug prices and upfront integration costs.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 March 2025–28 February 2026 |
| Net Sales | ¥54,982 million (YoY +13.6%) |
| Operating profit | ¥1,788 million (YoY +5.7%) |
| Ordinary income | ¥1,859 million (YoY +2.4%) |
| Profit attributable to owners of the parent | ¥1,275 million (YoY +12.5%) |
| Net income per share | ¥338.73 |
| Operating Margin | 3.3 % |
| Equity ratio | End of the current fiscal period 41.7 / End of previous period 41.2 |
| Total assets | ¥37,523 million |
| Net assets | ¥16,285 million |
| Cash flows from operating activities | ¥1,208 million |
| Cash flows from investing activities | ¥-1,814 million |
| Cash flows from financing activities | ¥-283 million |
| Cash and cash equivalents at end of period | ¥5,749 million |
| Full-year earnings forecast | Net Sales ¥56,500 million (YoY +2.8%) / Operating profit ¥1,800 million (YoY +0.7%) / Ordinary income ¥1,850 million (YoY -0.5%) / Profit attributable to owners of the parent ¥1,300 million (YoY +2.0%) |
| Annual Dividend Forecast | ¥65 → ¥120 |
| Payout ratio | 35.4% |
| Segment revenue | Dispensing Pharmacy Business ¥26,291 million (YoY +6.4%), Healthcare Business ¥8,990 million (YoY +10.7%), Pharmaceutical Wholesale Business ¥19,447 million (YoY +26.6%), Real Estate Business ¥254 million (YoY +24.8%) |
| Segment profit | Dispensing Pharmacy Business ¥1,373 million (YoY +11.3%), Healthcare Business ¥111 million (YoY -31.7%), Pharmaceutical Wholesale Business ¥287 million (YoY -16.7%), Real Estate Business ¥144 million (YoY +4.8%) |
| Depreciation and amortization | ¥722,462 thousand |
| Impairment loss | ¥1,648 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥4,736 thousand, Gain on sale of investment securities ¥228,484 thousand, Gain on bargain purchase ¥41,591 thousand, Government Subsidy Income ¥50,171 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥14,060 thousand, Impairment Losses ¥1,648 thousand, Loss on reduction of fixed assets ¥50,171 thousand, Directors' Retirement Benefits ¥2,050 thousand, Loss on sale of investment securities ¥147 thousand, Loss on cancellation of lease agreements ¥91,165 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No material changes. The number and names of newly consolidated or excluded companies are Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 3,770,000 |
| Treasury Shares at Period-End | 4,121 |
| Factors Behind Changes in Business Performance | Net sales increased due to the full-year contribution from acquired companies and new acquisitions through M&A, as well as higher prescription prices at dispensing pharmacies. The healthcare business reported lower profit due to higher personnel expenses, M&A expenses and upfront costs for newly established facilities, while the pharmaceutical wholesale business was affected by lower official drug prices and upfront integration costs. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The dispensing pharmacy business reported higher net sales due to higher prescription prices and the full-year contribution from acquisitions and acquired businesses. The healthcare and pharmaceutical wholesale businesses also reported higher net sales, supported by newly established facilities and acquired companies. Meanwhile, the healthcare business reported lower profit due to higher personnel expenses, M&A expenses and upfront costs for newly established facilities, while the pharmaceutical wholesale business was affected by lower official drug prices and upfront integration costs.